PHS
VKTX icon

PFM Health Sciences’s Viking Therapeutics VKTX Stock Holding History

PFM Health Sciences’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.96M Sell
255,330
-7,776
-3% -$251K 0.85% 44
2026
Q1 		$8.56M Buy
263,106
+74,150
+39% +$2.38M 0.78% 42
2025
Q4 		$6.65M Buy
188,956
+5,418
+3% +$192K 0.66% 46
2025
Q3 		$4.82M Buy
183,538
+145,809
+386% +$4.35M 0.37% 51
2025
Q2 		$1,000K Buy
+37,729
New +$993K 0.09% 55
2024
Q3 		– Sell
-58,811
Closed -$3.12M – 88
2024
Q2 		$3.12M Buy
58,811
+25,984
+79% +$1.7M 0.15% 62
2024
Q1 		$2.69M Buy
+32,827
New +$1.46M 0.13% 77

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PFM Health Sciences's VKTX Position: Q2 2026 in Review

PFM Health Sciences reduced its Viking Therapeutics (VKTX) stake by 3% in Q2 2026, selling an estimated $251K and leaving 255,330 shares worth $9.96M. The position accounts for 0.85% of the portfolio, ranked #44.

PFM Health Sciences first reported a position in VKTX in Q1 2024 and has held it in 7 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • PFM Health Sciences held 255,330 shares of Viking Therapeutics worth $9.96M as of Q2 2026.
  • PFM Health Sciences sold 7,776 Viking Therapeutics shares in Q2 2026, an estimated $251K.
  • Viking Therapeutics made up 0.85% of PFM Health Sciences's portfolio in Q2 2026, its #44 holding.
  • PFM Health Sciences first reported a position in Viking Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.